Neuroscientists at UCL have found no significant association between COVID-19 and the potentially paralysing and sometimes fatal neurological condition Guillain-Barré syndrome.
Researchers say the findings, published in the journal Brain*, along with a linked scientific commentary** by UCL and other international experts, should provide the public with reassurance, as the UK's national coronavirus vaccination programme is rolled out.
Guillain-Barré syndrome (GBS) is a rare but serious autoimmune condition that attacks the peripheral nervous system, typically affecting the feet, hands and limbs, causing numbness, weakness and pain. While its exact cause is unknown, GBS often occurs after a gastroenteritis infection called Camplylobacter, with the immune system mistakenly attacking nerves rather than germs.
GBS is usually reversible, however in severe cases it can cause prolonged paralysis involving breathing muscles, require ventilator support and sometimes leave permanent neurological deficits. Early recognition by expert neurologists is key to proper treatment.
Historical context of virus- and vaccine-associated GBS
More cases of GBS were associated with the Zika virus outbreaks in Latin America (2016 and 2020) than expected by chance alone; and concerns have been raised in GBS research reports that a similar link may potentially exist between COVID-19 infection and GBS too.
Researchers also say fears of a global rise in GBS following mass vaccination may persist due to a historic small increase in GBS associated with the 1976 swine flu vaccination campaign in the USA. This vaccination campaign was halted because the risk of developing GBS was statistically increased from background, although subsequent statistical analysis found the risk of a link to be lower than initially thought. In every flu vaccination campaign since, the risk of GBS as a result of flu vaccination is estimated to be about one per million vaccination doses.
This study
In this epidemiological and cohort study, UCL researchers sought to investigate any causative association between COVID-19 infection and GBS.
The team assessed the number of GBS treatments reported to the NHS England National Immunoglobulin Database between 2016 and 2019. This was compared to the number of cases reported during the COVID-19 pandemic in the first half of 2020.
The annual incidence of GBS treated in UK hospitals between 2016 and 2019 was 1.65-1.88 per 100,000 individuals. Incidences of GBS fell 40-50% between March and May 2020 when compared to the same months of 2016-2019. This new finding contradicts that of other smaller and less extensive international studies.
First author, Dr Stephen Keddie (UCL Queen Square Institute of Neurology) said: "The possibility of SARS-CoV-2 driving a global spike in GBS has been eagerly monitored with a number of published small case series already asserting a causal link. However, a surge in GBS cases after the SARS-CoV-2 pandemic has not been detected as happened in the Zika virus pandemic.
"Our epidemiological study shows there was no increased incidence in GBS during the first wave of COVID-19; rather, there was a decrease and therefore no causal link of COVID-19 to GBS can be made."
Separately in this study the research team also tried to establish if there was any genetic or protein structure in SARS-CoV-2, the virus that causes COVID-19, which could trigger an immune response causing GBS. Unlike Camplylobacter, which contains human-like antigens causing an autoimmune response, no credible link was found with SARS-CoV-2.
Dr Keddie added: "Most COVID-19 vaccinations are based on the SARS-CoV-2 spike protein, which drives a complex immune response creating antibodies to fight infection.
"Our analysis shows SARS-CoV-2 contains no additional immunogenic material known or proven to drive GBS. Concerns that COVID vaccination might cause GBS in any significant numbers are therefore almost certainly unfounded."
Around 1,500 cases of GBS occur in the UK each year (two per 100,000 population). History suggests, researchers say, that mass vaccination might be blamed for cases of GBS when occurring by chance, particularly with billions of people expected to be immunised globally.
Corresponding author, Professor Michael Lunn (UCL Queen Square Institute of Neurology) said: "When we immunise the population against COVID-19, GBS (and other neurological illnesses) will occur, by chance alone, in the weeks after immunisation, the window for a normal response to the vaccine.
"These cases may cause concern in patients, politicians, and regulators and stoke anti-vaccination concerns, even though it is likely that most, if not all of the cases, will be associated with vaccination by chance alone.
"Such a severe illness may result in suspension or withdrawal of vaccination as a 'knee jerk' safety reaction but this must not happen unless there is a statistically demonstrated link through careful monitoring that is proven. We must accept small risks with any vaccination programme on this scale, and these are far lower than the risk from COVID infection."
###
Notes to Editors
To speak with the researchers or for a copy of the paper please contact Henry Killworth, UCL Media Relations: T +44 (0) 7881 833274 or E: h.killworth@ucl.ac.uk Research paper, Stephen Keddie, Julia Pakpoor, Christina Mousele, Ainsling Carr, Michael Lunn, 'Epidemiological and cohort study finds no association between Covid-19 and Guillain-Barre syndrome' will be published in Brain, at 00:01 (UK Time) Monday 14 December 2020 / 19:01 (Eastern Time).
*The DOI for this Brain research paper will be: https://doi.org/10.1093/brain/awaa433
Scientific commentary, Michael Lunn, David Cornblath, Richard Hughes, Bart Jacobs, Pieetr Van Doorn, Hugh Willisson, 'COVID-19 vaccine and Guillain-Barre syndrome: Let's not leap to associations' will be will be published in Brain, at 00:01 (UK Time) Monday 14 December 2020 / 19:01 (Eastern Time).
**The DOI for the linked scientific commentary also published in Brain will be: https://doi.org/10.1093/brain/awaa444
About UCL - London's Global University
UCL is a diverse community with the freedom to challenge and think differently. Our community of more than 41,500 students from 150 countries and over 12,500 staff pursues academic excellence, breaks boundaries and makes a positive impact on real world problems. We are consistently ranked among the top 10 universities in the world and are one of only a handful of institutions rated as having the strongest academic reputation and the broadest research impact. We have a progressive and integrated approach to our teaching and research - championing innovation, creativity and cross-disciplinary working. We teach our students how to think, not what to think, and see them as partners, collaborators and contributors. For almost 200 years, we are proud to have opened higher education to students from a wide range of backgrounds and to change the way we create and share knowledge. We were the first in England to welcome women to university education and that courageous attitude and disruptive spirit is still alive today. We are UCL.
Journal
Brain